Cytogen, Inc.
Financials
Valuation Metrics
Cytogen, Inc.'s Market Cap is ₩535B. At end of 2025 it was ₩2079B. Ranked #1669 of 2,405 in KR market (top 69%), #999 of 1,627 on KOSDAQ (top 61%), #182 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 79%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 53.54B KRW | KR#1,669/2,405 Sec#182/231 |
| Revenue | 27.38B KRW | KR#2,052/2,405 Sec#143/231 |
| Net Income | -10.55B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 54.75B KRW | KR#2,155/2,405 Sec#191/231 |
| Net Assets | 33.75B KRW | KR#2,131/2,405 Sec#188/231 |
| Employees | 50 | KR#2,039/2,405 Sec#189/231 |
| Value | ||
| P/B | 1.59x | KR#1,843/2,405 Sec#133/231 |
| P/S | 1.96x | KR#1,842/2,405 Sec#107/231 |
| FCF Yield | -16.67% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -31.25% | KR#2,183/2,405 Sec#177/231 |
| ROA | -19.26% | KR#2,224/2,405 Sec#174/231 |
| Op. Margin | -23.94% | KR#2,135/2,405 Sec#150/231 |
| Revenue Growth | 31.63% | KR#365/2,405 Sec#36/231 |
| Financial Health | ||
| Debt Ratio | 62.24% | KR#1,116/2,405 Sec#133/231 |
| Total Debt | 13.12B KRW | KR#1,529/2,405 Sec#133/231 |
| FCF | -8.92B KRW | KR#1,661/2,405 Sec#143/231 |
| Cash | 14.89B KRW | KR#1,434/2,405 Sec#113/231 |
| Current Ratio | 7.49x | KR#160/2,405 Sec#36/231 |
| Performance | ||
| 1Y Return | -19.48% | KR#1,107/2,405 Sec#72/231 |
| 1M Return | -27.88% | KR#2,180/2,405 Sec#216/231 |
| From 52W High | -79.33% | KR#2,278/2,405 Sec#208/231 |
| 1Y MDD | -75.42% | KR#2,157/2,405 Sec#189/231 |
| Trading | ||
| Volume | 24,759 shares | KR#1,384/2,405 Sec#133/231 |
| Trading Value | 57.5M KRW | KR#1,657/2,405 Sec#174/231 |
| Foreign Own. | 2.04% | KR#1,605/2,405 Sec#156/231 |
| Per Share | ||
| EPS | -456 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,459 KRW | KR#2,209/2,405 Sec#193/231 |
Company Info
The company, established in 2013, is a precision medicine specialist firm with CTC-based liquid biopsy platform technology. In 2024, it diversified its business by acquiring Genome Care, a prenatal and postnatal diagnostics specialist, and now offers anti-cancer new drug development support to pharmaceutical companies, medical device distribution, and health functional food sales. Accelerating global market expansion with US and Japan subsidiaries, the company strengthens its position in the precision medicine market through technology commercialization in cooperation with major hospitals and pharmaceutical companies. Cytogen was established in 2010 and is headquartered in Songpa-gu, Seoul.